Technical Analysis for XENE - Xenon Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | 1.20% | |
| Gapped Up | Strength | 1.20% | |
| Fell Below 20 DMA | Bearish | 5.78% | |
| Inside Day | Range Contraction | 5.78% | |
| Gapped Down | Weakness | 5.78% | |
| Crossed Above 20 DMA | Bullish | 0.63% | |
| MACD Bullish Signal Line Cross | Bullish | 0.63% | |
| Pocket Pivot | Bullish Swing Setup | 0.63% | |
| Gapped Up | Strength | 0.63% |
| Alert | Time |
|---|---|
| Up 1% | about 13 hours ago |
| Possible Inside Day | about 14 hours ago |
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Down 1% | about 18 hours ago |
| Upper Bollinger Band Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Xenon Pharmaceuticals Inc. Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Organic Compounds Chemical Compounds Gene Therapy Cardiovascular Disease Knee Osteoarthritis Analgesics Pharmaceutical Industries Acne Lipoprotein Neuropathic Pain Treatment Of Osteoarthritis Teva Pharmaceutical Industries Treatment Of Cardiovascular Disease Alipogene Tiparvovec Erythromelalgia Glybera Lipase Lipoprotein Lipase Deficiency Postherpetic Neuralgia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 50.99 |
| 52 Week Low | 27.985 |
| Average Volume | 344,729 |
| 200-Day Moving Average | 39.79 |
| 50-Day Moving Average | 43.55 |
| 20-Day Moving Average | 41.46 |
| 10-Day Moving Average | 41.00 |
| Average True Range | 1.62 |
| RSI (14) | 54.34 |
| ADX | 22.73 |
| +DI | 18.31 |
| -DI | 15.72 |
| Chandelier Exit (Long, 3 ATRs) | 38.73 |
| Chandelier Exit (Short, 3 ATRs) | 43.70 |
| Upper Bollinger Bands | 43.75 |
| Lower Bollinger Band | 39.18 |
| Percent B (%b) | 0.84 |
| BandWidth | 11.02 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.77 |
| MACD Histogram | 0.3613 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.74 | ||||
| Resistance 3 (R3) | 44.55 | 43.78 | 44.45 | ||
| Resistance 2 (R2) | 43.78 | 43.34 | 43.88 | 44.35 | |
| Resistance 1 (R1) | 43.39 | 43.06 | 43.59 | 43.58 | 44.26 |
| Pivot Point | 42.62 | 42.62 | 42.72 | 42.72 | 42.62 |
| Support 1 (S1) | 42.23 | 42.18 | 42.43 | 42.42 | 41.74 |
| Support 2 (S2) | 41.46 | 41.90 | 41.56 | 41.65 | |
| Support 3 (S3) | 41.07 | 41.46 | 41.55 | ||
| Support 4 (S4) | 41.26 |
